Advertisement
U.S. markets open in 1 hour 4 minutes

Opthea Limited (OPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9100+0.2000 (+5.39%)
At close: 04:00PM EDT

Opthea Limited

650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
https://opthea.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.Founder, Chief Innovation Officer & Executive Director599.73kN/A1975
Ms. Judith J. Robertson B.A., M.B.A.Chief Commercial Officer588.59kN/A1961
Ms. Karen Adams CPAVP of Finance & Company Secretary305.14kN/A1972
Dr. Frederic Guerard M.S., Pharm.D.Chief Executive OfficerN/AN/A1973
Mr. Peter F. Lang M.B.A.Chief Financial OfficerN/AN/A1973
Ms. Sarika Gulhar Ph.D.Executive Director of Human ResourcesN/AN/AN/A
Dr. Michael Gerometta Ph.D.Head of Chemistry, Manufacturing & Controls Development130.17kN/A1965
Mr. Bruno Gagnon BPHARM, M.Sc.Senior Vice President of Global Clinical OperationsN/AN/A1969
Dr. Kenneth SallChief Medical OfficerN/AN/AN/A
Dr. Fang Li Ph.D.Senior Vice President of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Corporate Governance

Opthea Limited’s ISS Governance QualityScore as of March 1, 2024 is 9. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.